BioNTech SE (22UA.F)
109.00
-3.10 (-2.77%)
At close: Jan 14, 2025, 4:35 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 26.13B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.94 |
| PE Ratio (ttm) | -56.19 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 669 |
| Avg. Volume (20D) | 1,058 |
| Open | 112.10 |
| Previous Close | 112.10 |
| Day's Range | 109.00 - 114.50 |
| 52-Week Range | 69.70 - 124.60 |
| Beta | undefined |
About 22UA.F
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for tripl...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2019
Employees 6,133
Stock Exchange XETRA
Ticker Symbol 22UA.F
Website https://www.biontech.de